CytomX Therapeutics Inc (CTMX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
CytomX Therapeutics Inc stock (CTMX) is currently trading at $4.24. CytomX Therapeutics Inc PS ratio (Price-to-Sales) is 9.94. Analyst consensus price target for CTMX is $13.44. WallStSmart rates CTMX as Sell.
- CTMX PE ratio analysis and historical PE chart
- CTMX PS ratio (Price-to-Sales) history and trend
- CTMX intrinsic value — DCF, Graham Number, EPV models
- CTMX stock price prediction 2025 2026 2027 2028 2029 2030
- CTMX fair value vs current price
- CTMX insider transactions and insider buying
- Is CTMX undervalued or overvalued?
- CytomX Therapeutics Inc financial analysis — revenue, earnings, cash flow
- CTMX Piotroski F-Score and Altman Z-Score
- CTMX analyst price target and Smart Rating
CytomX Therapeutics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
CytomX Therapeutics Inc (CTMX) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in eps growth, institutional own.. Concerns around peg ratio and return on equity. Significant fundamental concerns warrant caution or avoidance.
CytomX Therapeutics Inc (CTMX) Key Strengths (2)
Earnings per share surging 60.60% year-over-year
72.80% of shares held by major funds and institutions
Supporting Valuation Data
CytomX Therapeutics Inc (CTMX) Areas to Watch (8)
PEG ratio is negative or unavailable
Company is destroying shareholder value
Losing money on operations
Revenue declining -98.30%, a shrinking business
Company is losing money with a negative profit margin
Very expensive at 9.9x annual revenue
Very expensive at 7.7x book value
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
CytomX Therapeutics Inc (CTMX) Detailed Analysis Report
Overall Assessment
This company scores 26/100 in our Smart Analysis, earning a F grade. Out of 10 metrics analyzed, 2 register as strengths (avg 10.0/10) while 8 fall into concern territory (avg 1.1/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on EPS Growth, Institutional Own.. Growth metrics are encouraging with EPS Growth at 60.60%.
The Bear Case
The primary concerns are PEG Ratio, Return on Equity, Operating Margin. Some valuation metrics including PEG Ratio (N/A), Price/Sales (9.94), Price/Book (7.65) suggest expensive pricing. Growth concerns include Revenue Growth at -98.30%, which may limit upside. Profitability pressure is visible in Return on Equity at -35.20%, Operating Margin at -3791.00%, Profit Margin at -22.80%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether PEG Ratio improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -35.20% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -98.30% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. PEG Ratio and Return on Equity are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
CTMX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
CTMX's Price-to-Sales ratio of 9.94x trades at a deep discount to its historical average of 65.22x (42th percentile). The current valuation is 98% below its historical high of 640.76x set in Nov 2015, and 1191% above its historical low of 0.77x in Mar 2025. Over the past 12 months, the PS ratio has expanded from ~0.8x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for CytomX Therapeutics Inc (CTMX) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
CytomX Therapeutics Inc is in a turnaround phase, with management focused on restoring profitability. Revenue reached 76M with 98% decline year-over-year. The company is currently unprofitable, posting a -22.8% profit margin.
Key Findings
Spending 27% of revenue (21M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 98% YoY. Worth determining whether this is cyclical or structural.
The company is unprofitable with a -22.8% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Volatility is elevated with a beta of 2.48, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact CytomX Therapeutics Inc.
Bottom Line
CytomX Therapeutics Inc is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(15 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 8:22:23 AM
About CytomX Therapeutics Inc(CTMX)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company in the United States. The company is headquartered in South San Francisco, California.